Q4 2022 Results slide image

Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology Immunology 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other 68 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation